EyePoint Pharmaceuticals priced an upsized public offering of common stock, expecting gross proceeds of $140 million.

From GlobeNewswire: 2024-10-29 21:47:43

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) priced an underwritten public offering of 12,727,273 shares of its common stock at $11.00 per share, expecting gross proceeds of approximately $140.0 million. The offering is expected to close on or about October 31, 2024. J.P. Morgan, Citigroup, and Guggenheim Securities are acting as joint book running managers, with EyePoint intending to use the net proceeds for clinical development of DURAVYU™ for retinal diseases, among other initiatives. The securities are being offered under a shelf registration statement on Form S-3. EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics for retinal diseases.

EyePoint Pharmaceuticals’ lead product candidate, DURAVYU™, is in Phase 3 global clinical trials for wet age-related macular degeneration (AMD) and Phase 2 trials for diabetic macular edema. The company’s pipeline includes other programs like EYP-2301 and razuprotafib, utilizing the Durasert E™ drug delivery technology. Vorolanib, a key component, is licensed exclusively by EyePoint. EyePoint emphasizes the safety and potential benefits of its technology in treating serious retinal diseases, with plans to release data from ongoing trials in the coming years. EyePoint is headquartered in Watertown, Massachusetts.



Read more at GlobeNewswire: EyePoint Pharmaceuticals Announces Pricing of Upsized